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Abstract
AIM: To evaluate the efficacy of human thrombin in 
the treatment of bleeding gastric and ectopic varices. 
METHODS: Retrospective observational study in a Ter-
tiary Referral Centre. Between January 1999-October 
2005, we identified 37 patients who were endoscopi-
cally treated with human thrombin injection therapy 
for bleeding gastric and ectopic varices. Patient details 
including age, gender and aetiology of liver disease/
segmental portal hypertension were documented. The 
thrombin was obtained from the Scottish National Blood 
Transfusion Service and prepared to give a solution of 
250 IU/mL which was injected via  a standard injection 
needle. All patient case notes were reviewed and the 
total dose of thrombin given along with the number of 
endoscopy sessions was recorded. Initial haemostasis 
rates, rebleeding rates and mortality were catalogued 
along with the incidence of any immediate compli-
cations which could be attributable to the thrombin 
therapy. The duration of follow up was also listed. The 
study was conducted according to the United Kingdom 
research ethics guidelines.
RESULTS: Thirty-seven patients were included. 33 
patients (89%) had thrombin (250 U/mL) for gastric 
varices, 2 (5.4%) for duodenal varices, 1 for rectal 
varices and 1 for gastric and rectal varices. (1) Gastric 
varices, an average of 15.2 mL of thrombin was used 
per patient. Re-bleeding occurred in 4 patients (10.8%), 
managed in 2 by a transjugular intrahepatic portosys-
temic shunt (TIPSS) (one unsuccessfully who died) and 
in other 2 by a distal splenorenal shunt; (2) Duodenal 
varices (or type 2 isolated gastric varices), an average 
of 12.5 mL was used per patient over 2-3 endoscopy 
sessions. Re-bleeding occurred in one patient, which 
was treated by TIPSS; and (3) Rectal varices, an aver-
age of 18.3 mL was used per patient over 3 endoscopy 
sessions. No re-bleeding occurred in this group.
CONCLUSION: Human thrombin is a safe, easy to use 
and effective therapeutic option to control haemorrhage 
from gastric and ectopic varices.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Haemorrhage from gastric or ectopic varices is associated 
with high morbidity and mortality and can account for 
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the presence of  oesophageal varices, the prevalence of  
gastric varices ranges from 15% to 100%[2,3] with the risk 
of  bleeding generally regarded to range from 4%-65% 
over the first 2 years after diagnosis[2,4]. More importantly 
it has been reported that although gastric varices are less 
likely to bleed than oesophageal varices, once they bleed, 
they tend to do so more severely and haemostasis can be 
difficult to achieve[2]. 
Unlike oesophageal variceal haemorrhage, bleeding 
from gastric varices has not been extensively studied. The 
natural history of  bleeding gastric varices differs from 
that of  oesophageal varices and thus the precipitating 
event for gastric variceal haemorrhage remains uncertain. 
Predictive factors for oesophageal variceal haemorrhage 
such as a hepatic venous pressure gradient (HVPG) of  
> 20 mmHg[5] is not felt to be as relevant to gastric vari-
ceal bleeding and this is partly attributed to the develop-
ment of  gastrorenal shunts. Indeed we have previously 
demonstrated that a portal pressure gradient (PPG) of  
< 12 mmHg does not necessarily protect against gastric 
variceal bleeding and that a PPG < 7 mmHg is a better 
safeguard against rebleeding[6]. The variceal size, tortu-
osity and stigmata of  recent bleeding such as red signs 
however remain alarming features[4].
Thrombin was first used for the management of  gas-
tric varices in 1947[7] and affects haemostasis by convert-
ing fibrinogen to a fibrin clot. It also has other influences 
on the coagulation system with one effect being the 
enhancement of  local platelet aggregation. Endoscopic 
treatment with thrombin has been reported in the treat-
ment of  bleeding oesophageal, gastric and duodenal 
varices[8-10] with a low rate of  rebleeding. The most recent 
study from Ramesh et al[11] reported that haemostasis was 
achieved in the acute setting in 92% patients present-
ing with bleeding gastric varices, with only one patients 
requiring a transjugular intrahepatic portosystemic shunt 
(TIPSS) to control bleeding. The majority of  these stud-
ies are however retrospective and include small patient 
numbers.
The aim of  this study is therefore to evaluate the use 
of  human thrombin in the treatment of  gastric and ec-
topic varices. 
MATERIALS AND METHODS
We identified 37 consecutive patients who were treated 
with human thrombin (Scottish National Blood Transfu-
sion Service) from January 1999-October 2005 for iso-
lated bleeding from gastric and ectopic varices. Thrombin 
was injected rather than cyanoacrylate as this was our 
Units protocol. The case notes were reviewed and total 
volume of  thrombin used and the incidence of  compli-
cations recorded, as was the incidence of  re-bleeding or 
death. Those patients with bleeding oesophageal varices 
who underwent banding of  varices or any patient in 
which there was diagnostic doubt as to the aetiology of  
bleeding were excluded. The study was conducted ac-
cording to the United Kingdom research ethics guide-
lines. Following consideration by the local ethics com-
mittee, further specific ethical review and approval was 
not required, as the study was considered a retrospective 
audit using anonymised data obtained as part of  usual 
patient care.
Patient characteristics
Twenty-eight of  the patients were male (male:female ra-
tio = 28:9) with a mean age at presentation of  53.2 years 
(range: 18-83 years). The underlying aetiology was alco-
holic liver disease in 15 patients, splenic vein thrombosis 
in 6, cryptogenic cirrhosis in 6, primary biliary cirrhosis 
in 2, chronic active hepatitis in 2, portal vein thrombosis 
in 2, primary sclerosing cholangitis in 2, α1-antitrypsin 
deficiency in 1, congenital hepatic fibrosis in 1 and hepa-
titis C in 1 patient. The Childs-Pugh grade: grade A = 5 
patients, grade B = 16 patients and grade C = 10 patients. 
Segmental portal hypertension was defined as extrahe-
patic portal hypertension in the absence of  liver cirrhosis 
and was seen in 6 patients whose underlying aetiology 
was splenic vein thrombosis.
Endoscopic therapy
All patients had an upper gastrointestinal endoscopy/
flexible sigmoidoscopy performed by an experienced 
operator within 12 h of  presentation. Gastric variceal 
haemorrhage was defined as visible spurting or oozing 
of  blood from the lesser curve or fundal vessels at the 
time of  endoscopy with varices subdivided into fundal 
and non fundal. Sarin’s classification for gastric varices 
was used but it was noted that it is often difficult to dif-
ferentiate the types of  fundal varices in patients who are 
actively bleeding. The gastric and duodenal varices were 
also considered to have bled if  there were stigmata of  
recent bleeding such as red spots or adherent clot. Rectal 
variceal haemorrhage was defined by the presence of  
rectal varices with either adherent clot or visible active 
bleeding combined with a history of  profuse fresh blood 
loss per rectum.
In those patients with splenic vein thrombosis, an al-
ternative therapy such as splenectomy may be considered 
by some but it is important that bleeding is controlled 
and therefore all these patients underwent endoscopy and 
stabilization of  bleeding prior to consideration for sple-
nectomy.
Protocol for thrombin therapy
All patients were adequately resuscitated at the time of  
endoscopy. Human thrombin concentrate obtained from 
the Scottish National Blood Transfusion Service and 
each vial was reconstituted with 5 mL of  water to give 
a concentration of  250 U/mL. As thrombin was being 
used outwith its licensed use, informed written consent 
was obtained from each patient prior to endoscopy. The 
thrombin was injected directly into the varices using a 
standard injection sclerotherapy needle to a maximum 
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volume of  10 mL at any one session by multiple injec-
tions. Repeat endoscopy was arranged initially for one 
week then at two weekly intervals until further injection 
was deemed unnecessary by the endoscopist as the over-
lying mucosa had returned to normal in which the varix 
appeared well covered with no stigmata of  recent haem-
orrhage. The number of  endoscopy sessions, the total 
volume of  thrombin used and the incidence of  complica-
tions were documented.
RESULTS
Thirty-three patients (89%) had thrombin for gastric 
varices, two (5.4%) for duodenal varices, one for rectal 
varices and one for gastric and rectal varices. A small 
number of  patients in this cohort were in our original 
pilot study[12]. Twenty seven patients (82%) also had 
oesophageal varices with 19 patients (58%) already in a 
banding programme. Only 3 patients were on beta-block-
er therapy prior to admission. The average total volume 
of  thrombin used per patient was 15.2 mL (range: 5-47.5 
mL, combined rectal and gastric varices) over 1-7 endos-
copy sessions (median 3.6 sessions). 
For those patients with gastric varices, 82% were clas-
sified as gastro-oesophageal varices (GOV) type 2 with 
the remainder being classified as isolated gastric varices 
(IGV) type 1 (12 %) and type 2 (6%). In two cases where 
it was not absolutely clear whether they were GOV type 
1 or type 2 they were included as type 2. An average of  
15.2 mL of  thrombin was used per patient (Figure 1). 
Re-bleeding occurred in four patients (10.8%), three of  
which bled before the 2nd endoscopy session (i.e., within 
7 d of  index bleed) and two of  whom were managed by 
TIPSS. One of  the TIPSS procedures was unsuccessful 
and the patient subsequently died after a rebleed. The 
two other patients were successfully treated by distal 
splenorenal shunt. 
For those two patients with duodenal varices, an aver-
age of  12.5 mL was used per patient over 2-3 endoscopy 
sessions. Re-bleeding occurred at day 3 in one patient 
which was treated successfully by TIPSS insertion.
For the patient with rectal varices, an absolute volume 
of  18.3 mL was used over three endoscopy sessions. No 
re-bleeding occurred in this group.
Only a small proportion of  patients (15%) had addi-
tional therapy with vasopressor agents, the use of  which 
did not change outcome. All patients with liver disease 
received five days of  intravenous antibiotics as per our 
units protocol. In addition, true eradication of  varices 
was rare with varices deemed visually eradicated in only 
two patients. No HVPG measurements were obtained in 
any patient as this is not our Units protocol. Overall mor-
tality was 2.7% after median follow up of  22 mo.
Complications
No clinically significant adverse events occurred follow-
ing thrombin therapy with median follow up of  22 mo.
DISCUSSION
Gastric varices are generally classified by their location 
in the stomach and their relationship with oesophageal 
varices, as proposed by Sarin et al[2]. GOV is the term 
used to describe gastric varices that are associated with 
oesophageal varices and are classified as either type 1 or 
type 2. IGV is used to refer to gastric varices that occur 
independently of  oesophageal varices. It is observed that 
type 1 GOV (which are primarily supplied by the left gas-
tric vein) represent 75% of  all gastric varices observed. 
However it is generally regarded that the most serious 
haemorrhage occurs when type 1 IGV gastric varices 
(primarily supplied by the short gastric vein) bleed. 
Various treatment options exist for the management 
of  bleeding gastric varices and include endoscopic meth-
ods, TIPSS and other radiological procedures. Surgical 
procedures such as under running of  gastric varices or 
devascularization procedures has previously been used 
but in the small studies performed have shown no great 
benefit and thus are rarely performed today. 
Although there is debate regarding optimum treat-
ment of  gastric variceal haemorrhage, endoscopic 
therapy is an established treatment and it is currently 
recommended in the United Kingdom to be the first line 
treatment in the management of  acute gastric variceal 
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Figure 1  Injection of gastric varices with thrombin. A: During thrombin injection the gastric varix swells; B: Post thrombin injection. 
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in bleeding gastric or ectopic varices has only previously 
been reported in a handful of  studies in which a variety 
of  thrombin preparations have been used. To our knowl-
edge, this study is currently the largest published study 
using human thrombin.
For the management of  bleeding gastric varices, our 
rates of  achieving initial haemostasis were in keeping 
with 93% published by Datta et al[10] and 100% by Wil-
liams et al[9]. Our rebleed rate of  14% was again in keep-
ing with data published by Williams et al[9] but it should 
however be recorded that the median follow up time in 
these studies varied greatly from six weeks to nine mo. 
It should also be documented that this rebleed rate was 
observed without us actively attempting to visually eradi-
cate the varices and may suggest that continued thrombin 
injection to achieve visual eradication appears unneces-
sary. This point was emphasised when we examined the 
number of  endoscopic sessions in which thrombin was 
given as initially the procedure was performed out to 7 
sessions. It was only after analysis of  these pilot data that 
rebleeding was deemed extremely rare after 3 endoscopic 
sessions and that eradication of  gastric varices was un-
necessary. It is therefore now our Units adopted policy 
that patients should be treated with thrombin for 3 en-
doscopic sessions. Overall, our mortality rate of  2.7% 
highlights how effective thrombin therapy can be, but it 
should be recorded that these results were obtained after 
5 patients who rebleed underwent further interventions: 
namely TIPSS or splenorenal shunt surgery.
The thrombin used in this study was obtained free of  
charge from Blood Transfusion Service but we have now 
changed to using a recombinant thrombin preparation at 
cost of  £250 for concentration of  250 IU/mL. This is 
comparable to the cost of  cyanoacrylate and the cost of  
TIPSS (at £5000).
Currently, no randomised controlled trials comparing 
thrombin with tissue adhesives or sclerotherapy have been 
performed. Interestingly however, Kojima et al[28] have 
published results for 30 patients with bleeding fundal 
varices that underwent sclerotherapy with ethanolamine 
under fluoroscopic guidance with the injection site be-
ing sealed with topical thrombin glue. All participants 
also received intravenous vasopressin and transdermal 
nitroglycerin. They reported an initial haemostasis rate 
of  93% with a rebleed rate of  19% after 5 years of  fol-
low up. The efficacy of  the topical thrombin is however 
difficult to determine and the specialized technique and 
equipment required for this procedure may limit its fu-
ture application. 
With regards to the safety of  human thrombin, we 
did not record any complications of  thrombin use and 
this is again in keeping with all of  the previously pub-
lished studies that have used human thrombin. Complica-
tions such as anaphylaxis or altered thrombogenesis that 
have previously been reported with the use of  bovine 
thrombin did not occur[29]. 
Although in this study we have not monitored the 
haemorrhage[13]. Endoscopic treatment options include 
standard sclerotherapy, band and snare ligation or endo-
scopic injection with cyanoacrylate or thrombin.
 Standard sclerotherapy using ethanolamine as the 
sclerosing agent has been used with moderate success 
in the treatment of  bleeding oesophageal varices but 
has limited success in the treatment of  bleeding gas-
tric varices. It is widely accepted that sclerotherapy for 
gastric varices requires significantly greater volumes of  
sclerosant[2] which is thought to account for the increased 
number of  side effects that are observed[14]. The initial 
haemostasis rates obtained when using sclerotherapy have 
been reported to vary widely from 26%-100%[11-16] which 
may reflect different operator ability and injection tech-
niques. However a rebleeding rate of  60%-90% has been 
reported in most studies which is generally observed in 
patients with bleeding fundal varices[1,17]. The majority of  
the rebleeding episodes have been reported to be related 
to ulceration at the injection site.
Endoscopic injection therapy with tissue adhesives 
such as cyanoacrylate has also been shown to be of  
benefit in the management of  bleeding gastric varices 
and is becoming more popular due to the high rebleed-
ing rates observed with sclerotherapy. A 90% success 
rate in achieving initial haemostasis has been reported 
in a number of  non randomised studies[18-20] but Ra-
mond et al[21] also reported a rebleeding rate of  50%. 
Several studies have also demonstrated that the use of  
tissue adhesives is superior to standard sclerotherapy. 
Oho et al[3] have published results of  a controlled but 
non-randomised study which demonstrated that initial 
control of  gastric variceal bleeding and survival was sig-
nificantly greater in patients treated with cyanoacrylate 
than standard sclerotherapy. Sarin et al[22] have published 
results for a small randomised control trial which again 
suggested that the use of  cyanoacrylate was superior to 
standard sclerotherapy. Complications rates between the 
two procedures have been reported to be similar but of  
course this depends primarily on the expertise available. 
In the hands of  inexperienced operators, tissue adhe-
sives can cause irreparable damage to the endoscope. In 
addition, a few centres have reported the occurrence of  
systemic emboli after the use of  tissue adhesives to con-
trol variceal haemorrhage[23,24]. 
Gastric variceal band ligation using ‘O’rings and de-
tachable snares have also been used in the management 
of  gastric variceal haemorrhage but with high rebleeding 
rates being observed[25]. Yoshida et al[26,27] have however 
published data on the combined use of  the detachable 
snare and simultaneous injection sclerotherapy and O-ring 
ligator. In a study of  43 patients[26], 97% had eradication 
of  gastric varices with an 8% rebleeding rate observed 
within a 2 year follow up period.
The optimal treatment for the management of  gastric 
varices therefore remains uncertain but as our results 
suggest, a promising therapeutic option is the use of  in-
travariceal injection of  thrombin. The use of  thrombin 
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effect of  thrombin by any means, we have evidence that 
results can be further improved by assessing clot forma-
tion with other means such as endoscopic ultrasound[30]. 
In conclusion, We have shown that human thrombin 
is a safe, easy to use and effective therapeutic option in 
the management of  bleeding gastric and ectopic varices. 
Our study also suggests that continued thrombin injec-
tion to achieve visual eradication appears unnecessary. 
Larger randomised control trials are necessary to com-




Haemorrhage from gastric or ectopic varices is associated with high morbidity 
and mortality and can account for up to one third of all cases of variceal haem-
orrhage.
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